28 C
Vientiane
Friday, June 27, 2025
spot_img
Home Blog Page 269

LG Display to Showcase World’s Best Solutions for Future Mobility at SID Display Week 2025

SEOUL, South Korea, May 6, 2025 /PRNewswire/ — LG Display, the world’s leading innovator of display technologies, announced today that it will participate in SID Display Week 2025, the world’s largest display exhibition, where it will showcase next-generation automotive displays.

LG Display’s stretchable automotive display
LG Display’s stretchable automotive display

SID Display Week draws together global display companies and researchers to present research papers on new technologies and exhibit medium- to long-term future technologies alongside new products. This year’s event is being held in San Jose, California, for three days from May 13 (local time).

LG Display plans to showcase the world’s best automotive displays optimized for future mobility under the theme “Driving the future.”

In line with the growing trend of larger and more numerous automotive displays amid the increasing importance of automotive infotainment systems, LG Display will introduce solutions that break boundaries in various aspects, including form, size, and picture quality.

With its Stretchable automotive display solution that can turn every interior space into a display, the company is presenting the potential for design innovation geared towards future mobility.

LG Display has maximized aesthetics and convenience by applying a Stretchable display to a vehicle’s center fascia area. The display can expand by up to 50% while maintaining a high resolution of 100 ppi (pixels per inch), comparable to that of a standard monitor, and full RGB color.

A conventional vehicle’s center fascia area requires a separate automotive display and physical buttons. With the application of a Stretchable display, however, the screen can freely expand, allowing the display and buttons to merge seamlessly into a single screen. When the screen is touched, the previously flat display flexibly expands and protrudes touch buttons, making it easy to operate even while driving.

The company will also showcase various world-leading form factor innovations, including a Pillar-to-Pillar product optimized for Software-Defined Vehicles (SDVs) and a Slidable OLED display that can be rolled up and hidden in a vehicle’s interior ceiling.

LG Display, which recently achieved the first commercialization of a 40-inch Pillar-to-Pillar display, will exhibit a 57-inch automotive Pillar-to-Pillar display, the largest in the world as a single panel.

It is an ultra-large solution that spans the dashboard from the driver’s seat to the front passenger’s seat. It allows the driver to view vehicle information such as driving data and the air conditioning system at a glance, while also enabling high-definition enjoyment of varied content like movies and games.

The 18-inch Slidable OLED display extends downward from the ceiling only when needed. With OLED’s distinctive three-dimensional image quality, it enables entertainment functions and provides a new mobility experience.

The Pillar-to-Pillar and Slidable product lines introduced this time have secured reliability and durability to ensure they operate normally even in extreme environments, from freezing cold as low as -40°C to the extreme heat of 85°C, making them suitable for automotive use.

With the trend of larger automotive displays, a key viewing angle control technology that enhances safety is being showcased, known as Switchable Privacy Mode (SPM).

As the first in the industry to commercialize SPM, LG Display’s innovation allows the front passenger to watch movies or play games on the area of the display in front of them, while driving safety is supported as the passenger’s entertainment content is kept invisible from the driver’s seat.

Having also become the world’s first to commercialize Tandem OLED for automotive displays in 2019, LG Display is strengthening its leadership in premium automotive displays based on its full lineup of related world-class technologies, including P-OLED, Advanced Thin OLED (ATO), and high-end LTPS LCD.

“At SID Display Week 2025, we will continue to showcase new technologies that can create differentiated customer value, solidifying our status as the global number one with the world’s best automotive displays,” said Keuk-sang Kwon, Head of Auto Business Group at LG Display.

About LG Display

LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world’s leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam. The company has approximately 70,707 employees operating worldwide. For more news and information about LG Display, please visit www.lgdisplay.com.

Media Contact:

Joo Yeon Jennifer Ha, Manager, Communication Team
Email: hjy05@lgdisplay.com 

Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025

SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announces that the latest 1-year results from its Phase 2 clinical trial of efdamrofusp alfa (R&D code: IBI302), a recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein, in Chinese subjects with neovascular age-related macular degeneration (nAMD) were presented orally at the 2025 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). The ARVO Annual Meeting 2025 is the premiere gathering of researchers and physicians in vision and ophthalmology to share the latest research findings and collaborate on innovative solutions, to be held from May 4 – 8 in Salt Lake City, Utah, U.S..

Title: Intravitreal High-dose Efdamrofusp Alfa (IBI302) in Patients with Neovascular Age-related Macular Degeneration: A Randomized, Double-masked, Active-controlled, Phase 2 Study
Presentation Number: 443
Presentation Format: Speech/Mini Oral
Presentation Time: May 4, 2:15pm-2:30pm
Presenter: Prof. Xiaodong Sun, Shanghai General Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment period. A total of 132 subjects were randomized 1: 1: 1 to IBI302 6.4 mg group, IBI302 8.0 mg group, or Aflibercept 2.0 mg group. After the loading therapy, IBI302 groups were administrated at personal treatment interval of Q12W or Q8W based on the disease activity assessed at Week 20. Subjects in Aflibercept 2.0 mg group were dosed Q8W after the loading therapy. The primary endpoint was the change in best corrected visual acuity (BCVA) in the study eye from baseline to week 40 and the study lasts 52 weeks. The results showed 6.4 mg/ 8.0 mg IBI302 competitive efficacy and safety profiles:

  • Potential for extended dosing interval regiment: Throughout the trial period, over 80% of participants in IBI302 groups maintained visual benefits with a 12-week dosing interval.
  • Comparable BCVA gains versus 2.0mg Aflibercept The trial met the primary endpoint, BCVA gains in 6.4mg/8.0mg IBI302 were noninferior to Aflibercept at week 40 the mean change from baseline +10.5[SD 9.6], +11.0[11.4], and +9.8[8.7] ETDRS letters, respectively. This improvement was sustained through week 52 with +10.8 [10.2], +11.3 [10.3], and +10.0 [9.0] letters compared to baseline.
  • Anatomical efficacy improvement versus 2.0mg Aflibercept: At week 52, the mean change of central subfield thickness (CST) reductions from baseline was 154.58 [149.17] μm for the IBI302 6.4 mg group, 174.69 [147.04] μm for the IBI302 8.0 mg group, and 131.18 [102.91] μm reduction for the Aflibercept 2.0 mg group, respectively.
  • Potential to inhibit macular atrophy: Data from pooled analyses of two Phase 2 clinical trials (CIBI302A201 and CIBI302A202) suggested that IBI302 treatment may reduce the incidence of MA at Week 52 by nearly 40% compared to aflibercept (4.9% in IBI302 groups vs. 8.3% in Aflibercept group) .
  • The incidences of adverse events in IBI302 groups were similar to Aflibercept. No retinal vasculitis occurred in this trial. No new safety signals were identified.

Professor Xiaodong Sun, Principal Investigator of the Study, Deputy director, Head of National Center for Clinical Ophthalmology, Shanghai General Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, stated: “It is my privilege to present the latest research findings on IBI302 to the global ophthalmic community at the ARVO meeting as the principal investigator. While anti-VEGF drugs remain the first-line therapy for nAMD, the frequency of  intravitreal injections and follow-up visits can significantly impact patient compliance. Current drug development focuses on multi-target strategies and extended dosing intervals to reduce the treatment burden by decreasing injection frequency. Notably, IBI302—a novel global first-in-class bispecific molecule (anti-VEGF/anti-complement) —recently reported Phase 2 data showing that its high-dose cohorts met the primary endpoint. The treatment group achieved approximately 10-letters improvement in visual acuity from baseline at one year, with over 80% subjects demonstrating potential for at least 12-weeks extended dosing intervals. Additionally, preliminary observations in IBI302 group suggest potential efficacy in inhibition of macular atrophy. We anticipate this innovative therapy will successfully complete the Phase 3 registration trial, providing nAMD patients with more effective, patient-friendly options.”

Dr. Lei Qian, Senior Vice President of Clinical Development of Innovent, stated: “We are honored to present the latest progress of IBI302 in its second Phase 2 clinical trial at the ARVO annual meeting. High dose IBI302 demonstrates positive efficacy in visual acuity and anatomical improvements, while extend dosing intervals and potential anti-macular atrophy effects. Additionally, no new safety signals were observed during the trial, further validating the favorable safety and tolerability profile of this agent. These encouraging results establish a robust foundation for subsequent development. We will continue collaborating with clinical experts to expedite the Phase 3 clinical trial program, and accelerate the availability of this innovative therapy for patients with nAMD.”

About Efdamrofusp Alfa (IBI302)

IBI302 is a recombinant fully human bispecific fusion protein of Innovent Biologics with global proprietary rights. The N- terminal is a VEGF domain that can bind to the VEGF family, block VEGF-mediated signaling pathway, inhibit vascular epithelium proliferation and angiogenesis, and improve vasopermeability and reduce leakage. The C- terminal of IBI302 is the complement binding domain that can inhibit the activation of the classic pathway and alternative pathway of complement through the specific binding of C3b and C4b, and reduce the inflammatory response mediated by the complement. IBI302 may exert its therapeutic effect by inhibiting both VEGF-mediated angiogenesis and complement activation pathways.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1)Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2)Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent Biologics (“Innovent”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or is otherwise inaccurate.

Smart Digital Group Limited Announces Closing of Initial Public Offering

SINGAPORE, May 6, 2025 /PRNewswire/ – Smart Digital Group Limited (the “Company”) (Nasdaq: SDM), a digital marketing service provider in Singapore, today announced the closing of its initial public offering (the “Offering”) of 1,500,000 ordinary shares, par value $0.001 per share (“Ordinary Shares”), at a public offering price of US$4.00 per share.

The Company received aggregate gross proceeds of US$6.0 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 225,000 Ordinary Shares at the public offering price, less underwriting discounts. The Ordinary Shares began trading on the Nasdaq Capital Market on May 2, 2025 under the ticker symbol “SDM.”

Proceeds from the Offering will be used for business expansion, brand promotion and marketing, software development, and for working capital and other general corporate purposes.

The Offering is being conducted on a firm commitment basis. US Tiger Securities, Inc. is acting as the sole book-runner for the Offering. Hunter Taubman Fischer & Li LLC is acting as counsel to the Company, and VCL Law LLP is acting as counsel to the underwriters in connection with the Offering.

A registration statement on Form F-1 relating to the Offering was filed with the Securities and Exchange Commission (the “SEC”) (File Number: 333-283152) and was declared effective by the SEC on May 1, 2025. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the Offering may be obtained from US Tiger Securities, Inc. by email at ECM@ustigersecurities.com, by calling +1 646-978-5188, or by standard mail to 437 Madison Avenue, 27th Floor, New York, New York 10022. In addition, a copy of the prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Smart Digital Group Limited

Smart Digital Group Limited is a digital marketing service provider headquartered in Singapore. The Company provides event planning and execution services, internet media services, software customization and marketing services and business planning and consulting services. For more information, visit the Company’s website at http://www.sdmmeta.com/.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial

BEIJING, May 6, 2025 /PRNewswire/ — Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagonist, with the first patient successfully dosed. As the first globally innovative drug targeting chronic post-surgical neuropathic pain (CPSP) to enter Phase II clinical development, TRD205 is positioned to overcome the limitations of existing opioid therapies and provide a safer, more effective solution for hundreds of millions of patients worldwide.

Mechanistic Breakthrough: Pioneering Non-Opioid Analgesic Pathways via AT2R Targeting

CPSP affects approximately 10% of surgical patients globally, translating to over 30 million cases annually. Current treatments face significant constraints: opioids demonstrate efficacy in only 25% of patients while carrying risks of addiction and depression, whereas NSAIDs and antidepressants show limited efficacy against neuropathic pain. TRD205’s core innovation lies in its precise inhibition of AT2R, a receptor whose abnormal activation post-peripheral nerve injury triggers macrophages to release reactive oxygen/nitrogen species. This process exacerbates calcium influx in dorsal root ganglion (DRG) sensory neurons, amplifying pain sensitization. By selectively blocking this pathway, TRD205 suppresses pain signaling at its source without engaging the central nervous system, thereby avoiding opioid-related risks such as addiction and respiratory depression. The drug has secured clinical trial approvals from both the U.S. FDA and China’s NMPA, with Phase I trials in healthy Chinese volunteers confirming favorable safety and pharmacokinetic profiles.

Addressing the Urgent Unmet Need in CPSP: A Public Health Priority

CPSP defined as pain persisting for over three months following surgery, impacts approximately 10% of the 320 million annual surgical patients globally. It is particularly prevalent after procedures such as limb amputation (50%-85%), thoracotomy (30%-50%), breast surgery (25%-50%), and hernia repair (5%-35%), etc. Beyond physical suffering, CPSP is closely linked to anxiety, depression, and other symptoms. Existing therapies address less than 30% of clinical demand, highlighting the critical need for novel mechanisms like TRD205’s opioid-free approach. The Phase II study plans to enroll 184 patients with CPSP to evaluate pain score (NRS) improvements across dose groups over a six-week period.

Market Potential and Strategic Positioning in a $10 Billion Landscape

Global AT2R-targeted drug development remains nascent, with only a few competitors like Lilly-partnered CFTX-1554 (Phase I). TRD205’s approval would make it the first AT2R therapy for CPSP, with expansion potential into indications such as diabetic neuropathy and postherpetic neuralgia—a combined market exceeding $10 billion.

TRD205’s Phase II trial initiation marks a pivotal transition from opioid-dependent analgesia to precision targeting. Successful clinical validation would deliver a novel therapeutic paradigm for over hundreds of millions of patients globally.

Unlocking innovation: Endeavour Energy and mPrest expand partnership to enhance management of community batteries

SYDNEY and TEL AVIV, Israel, May 6, 2025 /PRNewswire/ — Endeavour Energy and mPrest today announced the expansion of their strategic collaboration to deliver a dynamic market-network approach to energy storage and flexibility which enables customers, retailers and networks to work together to maximise the value of local energy resources.

 

 

At the heart of this expanded partnership is the broader deployment of mPrest’s Distributed Energy Resource Management System (mDERMS), which enables real-time monitoring and control of Endeavour Energy’s growing fleet of community batteries.

The mDERMS platform enables real-time optimisation of both network assets and customer-owned technologies such as rooftop solar and batteries, with advanced visibility, forecasting, and control over local demand, generation, and grid constraints – supporting smarter use of locally generated renewables while enhancing power quality, reliability, and energy flow efficiency.

By providing real-time data access to energy retailers and aggregators, the platform creates opportunities for innovative new products that expand customer choice, flexibility, and engagement to enhance participation in broader energy markets, helping to maximise customers’ use of renewable energy and strengthen grid stability.

Endeavour Energy has already deployed mDERMS to oversee its community microgrid and Virtual Power Plant (VPP) in Bawley Point and Kioloa on the NSW South Coast. This next phase will scale those capabilities to support one of New South Wales’ largest community battery initiatives.

In partnership with the Australian Government, Endeavour Energy is deploying the largest community battery program in NSW and is nearing completion in the rollout of 76 community batteries across 33 suburbs to give households access to more affordable, sustainable energy through shared renewable storage.

The integration of MPrest’s mDERMS solution will mark another significant step toward a smarter, more sustainable energy future for Endeavour Energy customers by supporting innovation and creating more flexibility in local energy markets.

Quotes attributable to Endeavour Energy

Endeavour Energy’s General Manager Future Grid and Asset Management, Colin Crisafulli: “Our vision is to lead the transition to smarter, more sustainable energy solutions which provide our customers with greater choices and access to renewable energy options for a more sustainable energy future.In partnership with the Federal Government, we are delivering the largest community battery program in NSW, and this extended partnership with mPrest will further enhance local grid resilience by increasing Customer Energy Resources hosting capacity as well as providing opportunities for retailers and aggregators to desing new products and services for our customers.” 

Quotes attributable to mPrest

mPrest Chief Executive Officer Natan Barak: echoed this sentiment, noting that the development of this critical use case demonstrates the depth of collaboration between both companies. “Now is the time for transformative change in the energy landscape, and we are proud to partner with Endeavour Energy to empower communities for a sustainable energy future,” he said. Additionally, this distinct use case highlights additional mDERMS capabilities, providing support and advantages for utilities, VPPs, retailers, C&I sectors, and customers alike. 

mPrest Chief Commercial Officer Ron Halpern: highlighted the significance of the Australian market, “We are honoured to play a pivotal role in supporting Australia’s leading renewable energy sector through key initiatives such as Endeavour Energy’s microgrid and community battery projects. As the global market evolves, Australia’s advancements in renewable CER/DER and DERMS will serve as a model for others to follow.” 

Media enquiries:
•  Endeavour Energy: 0409 664 608 CorporateComms@endeavourenergy.com.au
•  mPrest: info@mprest.com  

About Endeavour Energy 
Endeavour Energy is one of Australia’s most efficient electricity distribution networks, powering NSW’s fastest growing economies and sustaining the jobs and lifestyles of 2.7 million Australians, living, and working in Central West NSW, The Blue Mountains, Greater Western Sydney, Southern Highlands, Illawarra and South Coast of NSW.

Since 1890, we have expanded our footprint to be at the forefront of Australia’s energy industry in integrating traditional and renewable energy sources to deliver a smarter, cleaner, affordable and more reliable energy system, with clear commitments and pathways to creating sustainable value for customers and communities. Endeavour Energy is committed to decarbonising the grid by 2035. Our mission is to leverage the latest technology and data to plan the grid of tomorrow where batteries, microgrids and solar integrate seamlessly with the traditional distribution network to power communities for a brighter future.

About mPrest 
Leveraging its unparalleled experience and expertise in real-time mission-critical command and control software, mPrest has developed the world-leading distributed asset orchestration and optimization software. mPrest’s micro-services based, real-time orchestration and optimization platform brings the power of AI and IoT to the digital transformation of the energy and other industrial IOT markets. mPrest’s applications suite, including Distributed Energy Resources Management Systems (DERMS) and Asset Health Management (AHM) are deployed on premise or in the cloud in record time in the most forward-looking and efficient organizations worldwide, including some of the world’s largest energy companies. mPrest’s vendor-agnostic product suite interfaces with millions of sensors, devices, machines, assets, subsystems, IT and OT applications, creating a system of systems that provides end-to-end visibility and control over complex and distributed operations. Visit us at www.mprest.com.

Trimble Announces Dimensions Australia, Expanding Access to Flagship User Conference Experience

Event Highlights Innovation in Connected Construction and Geospatial Technology in the Asia-Pacific Region

Registration is Now Open

WESTMINSTER, Colo., May 6, 2025 /PRNewswire/ — Trimble (Nasdaq: TRMB) is excited to announce Trimble Dimensions Australia, a new regional user conference taking place August 27-28 in Brisbane, Australia. Tailored for engineering and construction professionals, the conference provides two days of fast-paced education on innovative technology solutions, and dedicated opportunities to connect with peers and product experts.

Trimble Announces Dimensions Australia, Expanding Access to Flagship User Conference Experience
Trimble Announces Dimensions Australia, Expanding Access to Flagship User Conference Experience

Trimble’s renowned Dimensions Offsite Expo will be a key feature of the event, showcasing the latest machine control, monitoring, mapping and positioning technologies in live action as well as numerous hands-on learning opportunities.

In addition, attendees will be able to explore the convergence of the physical and digital worlds through:

  • Understanding the Impact of Artificial Intelligence (AI) technologies on the engineering and construction industry.
  • 50+ Educational Sessions to gain practical insights and learn from industry leaders.
  • Hands-on Technology Labs to experience the latest technology innovations and learn how to unlock maximum value from Trimble solutions.
  • A Unique Scanning Experience Center to discover the power of 3D scanning and reality capture.

Keynote: Future of Connected Construction
Trimble executives will kick off Dimensions Australia with a compelling keynote, showcasing the latest Trimble innovations and their impact on the construction project lifecycle. Through real-world examples, Trimble executives will demonstrate how connected data and emerging technologies are driving collaboration, productivity, efficiency and sustainability.

Join Us in Australia
Registration is open. The Star Brisbane Hotel will serve as the hub for this one-of-a-kind event, bringing hundreds of construction and engineering professionals together. Don’t miss this opportunity to:

  • Connect: Network with industry peers and Trimble experts.
  • Discover: Explore the latest technology advancements from Trimble.
  • Innovate: Gain the tools to solve today’s challenges and shape tomorrow’s industry.

For more information and to register, please visit: https://www.trimble.com/en/our-company/events/dimensions-australia/overview

About Trimble
Trimble is a global technology company that connects the physical and digital worlds, transforming the ways work gets done. With relentless innovation in precise positioning, modeling and data analytics, Trimble enables essential industries including construction, geospatial and transportation. Whether it’s helping customers build and maintain infrastructure, design and construct buildings, optimize global supply chains or map the world, Trimble is at the forefront, driving productivity and progress. For more information about Trimble (Nasdaq: TRMB), visit: www.trimble.com.

GTRMB

 

INTREPID Alliance Releases New Report Highlighting Urgent Gaps in Antiviral Preparedness

Global antiviral R&D is slowing when the world can least afford it,  new analysis shows

CAMBRIDGE, Mass., May 6, 2025 /PRNewswire/ — The INTREPID Alliance today released the fourth edition of its Antiviral Clinical and Preclinical Development Landscape, a comprehensive analysis of the global pipeline of small-molecule antiviral compounds. The findings reveal a concerning trend: rather than accelerating in response to global preparedness goals, antiviral R&D momentum is stalling. Drawing on data from over 200 clinical and preclinical antiviral programs across 13 viral families prioritized for pandemic preparedness, the report provides a timely snapshot of where progress is being made – and where gaps remain.

The landscape still shows that the majority of clinical and preclinical compounds under investigation are targeting the viruses where infection can lead to outbreaks of COVID-19 and influenza. Other indications where limited clinical and/or preclinical development work is underway include Mpox, Dengue, Ebola, and Lassa fever, among others. However, there are several viral families of pandemic potential with no compounds in clinical or preclinical development at this time leaving the world at risk of future outbreaks.

“We are going backwards, not forwards,” said James Anderson, Executive Director of Global Health at the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Chair of the INTREPID Alliance Board. “Despite the lessons of COVID-19, global investment in small-molecule antivirals is declining just when we need to be scaling up. Without a robust antiviral pipeline, the world remains dangerously exposed to emerging viral threats. This landscape is both a wake-up call and a roadmap for smarter, faster preparedness.”

Key Findings from the 4th Edition Landscape: *

  • Clinical pipeline: 67 distinct antiviral compounds are currently in active clinical development, with 22 approved compounds and 42 of those being novel, unapproved candidates. However, the overall number of promising new clinical candidates has not increased since the previous edition, highlighting a plateau in progress.
  • Preclinical pipeline: 168 novel compounds are in preclinical development, associated with 189 virus-disease indications. Yet the majority of these still target SARS-CoV-2, leaving many pandemic-priority viral families under-addressed.
  • R&D concentration: While nearly 90% of clinical development activity is being led by biopharmaceutical companies, early-stage research is more diverse, with contributions from academia and government labs. Still, most programs are concentrated in high-income countries, underscoring the need for more widespread global engagement.

The recent outbreaks of Mpox disease, which sparked the World Health Organization to declare public health emergencies of international concern,1,2 should be a wake-up call to the international community that the world is not immune to emerging and future outbreaks. The INTREPID Alliance Report on Direct-Acting Antivirals for Mpox, published last month highlights the urgent need for increased research and development of antiviral treatments for monkey pox virus and other orthopoxviruses with pandemic potential.

“In our interconnected world, a strong antiviral pipeline is not just a scientific issue – it’s a global security issue,” said Kelly Chibale, Ph.D., Professor, Neville Isdell Chair in African-centric Drug Discovery and Development, University of Cape Town. “We need to make sure innovation is not only happening but also reaching the places most vulnerable to future outbreaks. The INTREPID Landscape is a critical tool for making smarter, more informed decisions.” As a member of its Scientific Advisory Board, Professor Chibale is one of the scientific experts from around the world who advises INTREPID’s work.

INTREPID’s bi-annual antiviral pipeline reports are a key contribution to the 100 Days Mission, whose aim is to be prepared as much as possible so that within the first 100 days of a new pandemic threat being identified, interventions can be made available, safe, effective, and affordable. INTREPID’s research is freely available and is intended to support policymakers, funders, and the global scientific community in identifying the most urgent needs and highest-impact opportunities in antiviral R&D.

The full landscape report, study methodology, and an interactive antiviral clinical development pipeline are available at the INTREPID website. The INTREPID Alliance deep dive report focused on direct-acting antivirals for Mpox is also available through the website’s Deep Dive Reports section.

Disclaimer

The INTREPID Alliance is a non-profit consortium of innovative biopharmaceutical companies and associations committed to accelerating the development of antivirals for epidemic and pandemic threats. Through independent landscape analysis and policy engagement, the Alliance supports science-based investment and preparedness strategies aligned with global public health goals. 

As part of our efforts, the INTREPID Alliance maintains and publishes a centralized list of promising investigational candidate compounds, with the purpose of knowledge-sharing and to support better pandemic preparedness. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm’s length from commercial influence of our member companies. See criteria listed in the report “Antiviral Clinical Development Landscape and Promising Clinical Compounds.” The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria. “Promising” is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.

ABOUT THE INTREPID ALLIANCE

The INTREPID Alliance aims to accelerate the development of new treatments for emerging viral pandemic agents through facilitating early science and R&D, policy and advocacy, and stakeholder engagement. Led by a not-for-profit consortium of innovative biopharmaceutical companies and associations and working with the public, private and not-for-profit sectors, INTREPID works to bridge key gaps and unmet needs to ensure delivery of antiviral solutions to viral pathogens with the greatest pandemic potential.

INTREPID was launched in March 2023 at a high-level summit bringing together more than 100 thought leaders in virology and global health. For a read-out from the summit and additional information, visit www.intrepidalliance.org.

* As of December 18, 2024

1 World Health Organization (WHO). WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. (23 July 2022).
2 World Health Organization (WHO). WHO Director-General declares mpox outbreak a public health emergency of international concern. (14 August 2024).

 

YäRKEN Raises Funds from 1982 Ventures to Expand AI-Driven IT Financial Management Across North American Enterprise Clients

NEW YORK, May 6, 2025 /PRNewswire/ — YäRKEN, the first AI native IT Financial Management (ITFM) platform for enterprise clients has announced a fundraising round led by 1982 Ventures. This funding will enable YäRKEN to further develop its AI capabilities and scale its customer base across North America.

The ITFM market is projected to grow at 12.7% per annum and hit US$14 billion (according to Business Research Insights, forecast period 2025-2033). This growth is driven by CIOs’ increasing need for solutions to effectively manage and forecast complex cloud and on-premises investments as well as managing software licences and usage across multiple business units. Yarken’s AI-native approach reduces implementation times, delivers average cost reductions of 15-25%, and significantly reduces ongoing maintenance hours by up to 50%.

Yarken was founded by seasoned entrepreneurs Ravi Kuppan (CEO) and Vaibhav Kulkarni (CTO), after the successful sale of their enterprise software company Tarantula Global to Constellation Software. Kuppan said, “Our years delivering software to large global enterprises showed us CIOs are struggling to manage sprawling IT infrastructure costs with legacy solutions and spreadsheets that are inflexible, slow to deploy, and expensive to maintain. We knew how to solve this by leveraging AI.”

Ravi Kuppan, Yarken CEO stated, “Yarken’s native AI can ingest and analyze data from any IT system, regardless of format. This means whether you’re tracking cloud spending, software licenses, or hardware assets, our clients gain comprehensive, actionable cost insights months faster than our competitors.” He added, “Yarken’s platform provides comprehensive audit trails and cost transparency, helping enterprises maintain compliance and enhance IT governance.”

Yarken, which was recently included in Gartner’s 2025 Market Guide for ITFM as an established offering, has been rapidly expanding in the United States and Canada.  US based Maryville Consulting, recognized for its expertise in Technology Business Management, will now offer Yarken’s platform to its extensive portfolio of enterprise clients, giving them streamlined access to Yarken’s powerful analytics and cost management tools.

“Yarken’s light TBM approach and ease of use help us provide innovative solutions to the North American market. By integrating Yarken’s platform into our service offerings, we can help clients gain deeper insights into IT spend and drive more strategic decision-making.” said Quinn Abraham, VP of TBM / FinOps at Maryville Consulting.

“Many CIOs are faced with the competing mandates of reducing costs while continuing to invest in new systems. Yarken’s AI-native platform gives CIOs full visibility on their tech spend, with integrated forecasting and benchmarking that produce actionable insights, including rapid IT planning capabilities, allowing for proactive budget adjustments that the business can collaborate on. The solution pays for itself,” said James Kim, Operating Partner of 1982 Ventures and former Managing Director at Accenture. He added, “Yarken is the only platform that integrates all areas of IT financial management and cloud operations with native AI, allowing enterprise clients to achieve faster time to value.”

Scott Krivokopich, Founding Managing Partner at 1982 Ventures, stated, “We are excited to support founders like Ravi and Vaibhav, who have a proven track record of building and exiting successful enterprise software companies. Our investment in Yarken fits perfectly within our strategy of backing companies that are leveraging AI to transform financial services and enterprise operations. Yarken’s innovative approach to IT financial management, powered by native AI, is precisely the kind of disruption we believe will reshape the industry.”

The funding will fuel Yarken’s next phase of growth. Specifically, the company plans to aggressively expand its customer base across North America, further develop its AI capabilities and scale operational capacity to support this growth. Building on the success of global SI partnerships.  Yarken is also exploring more strategic partners with key industry players to broaden its market reach and further enhance its service offerings.

Kuppan added, “We’re just getting started.  This investment enables us to deliver even more value to our customers and partners as we redefine how enterprises manage IT spend.”

About Yarken:

YäRKEN is a leading AI-native IT Financial Management (ITFM) solution provider recognized for its innovative approach and featured in Gartner’s Market Guide for ITFM 2025. Yarken enables businesses to gain complete visibility into their IT spend, optimize costs, and make strategic decisions through AI-driven insights, forecasting, and benchmarking. Yarken’s platform simplifies ITFM, providing faster implementation, enterprise-grade scalability, and robust analytics.

For more information, visit: www.yarken.com